NCT06063850

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2024-06-12Est. Completion: 2026-11-30

Enrollment target: 12 participants

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic Arizona, Phoenix, Arizona, United States
Stanford University, Palo Alto, California, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
Kansas University Medical Center, Kansas City, Kansas, United States
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Midatlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Corewell Health, Grand Rapids, Michigan, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States
Robert Wood Johnson Hospital, New Brunswick, New Jersey, United States
Cleveland Clinic, Cleveland, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Allegheny Health Network, Pittsburgh, Pennsylvania, United States

Mesial Temporal Lobe Epilepsy

This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve c…

Birmingham, United StatesEst. completion Feb 2029

Patients With Drug-resistant Focal EpilepsySEEG as Part of Presurgical Evaluation

Interactions between epilepsy and sleep are numerous and bidirectional. Sleep can facilitate epileptic activity and seiz…

Durham, United StatesEst. completion Jun 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.